Image of lluminated lightbulb being held by both a doctor and patient

JEMPERLI resources for healthcare professionals

We have compiled a series of videos from ASCO 2022 to support you and your patients who have been prescribed JEMPERLI.

JEMPERLI at ASCO 2022 highlights

Exploring the Clinical Impact of the longer-term follow-up from the GARNET trial

Dr. Rowan Miller discusses the latest analysis from the GARNET trial

Dr. Ana Oaknin discusses the latest analysis from the GARNET trial

Downloadable resources

JEMPERLI dosing and administration guide

GARNET trial clinical slide deck

How can JEMPERLI help your next patient?

JEMPERLI is indicated as monotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer (EC) that has progressed on or following prior treatment with a platinum-containing regimen.1

References

  1. JEMPERLI (dostarlimab) Summary of Product Characteristics.

Adverse events should be reported.
Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store.

Adverse events should also be reported to GlaxoSmithKline on 0800 221 441 or via uksafety@gsk.com

© 2022 GSK Group of Companies or its licensor. Trademarks are the property of their respective owners.

June 2022 ӏ PM-GB-DST-WCNT-220007 (V1.0)